Zydus Lifesciences Limited clinical trials

Also known as Zydus Cadila.

The registry lists 103 studies whose lead sponsor is Zydus Lifesciences Limited or one of 4 companies grouped under it. 9 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 30, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 103. Browse all 103 →

• A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive ChemotherapyRecruitingNCT04570423Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA TherapyRecruitingNCT07424677Phase 3

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Hepatic Impairment With Cirrhosis Due to Cholestatic Liver DiseaseRecruitingNCT05045482Phase 1

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver DiseaseRecruitingNCT06825559Phase 1

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral SclerosisRecruitingNCT07023835Phase 2

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical OutcomesRecruitingNCT07216235Phase 3

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)RecruitingNCT05515367Phase 4
• A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum CarriersRecruitingNCT05911828Phase 1
• A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With ComorbiditiesRecruitingNCT05872269Phase 4
• A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 MutationsSuspendedNCT05378763Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With FibrosisCompletedNCT05011305Phase 2

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Saroglitazar Magnesium for Treatment of Primary Biliary CholangitisCompletedNCT05133336Phase 2/3

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to PoziotinibTerminatedNCT03744715Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationTerminatedNCT03318939Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary CholangitisActive, not recruitingNCT06427395Phase 3

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Copper Histidinate Treatment for Menkes DiseaseApproved for marketingNCT04074512

  Sponsor listed in the registry: Sentynl Therapeutics, Inc. · First submitted after Sentynl Therapeutics, Inc. became part of Zydus Lifesciences Limited

• Long Term Follow-up on Menkes Disease PatientsActive, not recruitingNCT04337684

  Sponsor listed in the registry: Sentynl Therapeutics, Inc. · First submitted after Sentynl Therapeutics, Inc. became part of Zydus Lifesciences Limited

• Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)TerminatedNCT03617263Phase 2

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the USTerminatedNCT05211284Phase 2

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral AminosalicylatesCompletedNCT06398808Phase 2
• Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral SclerosisCompletedNCT05981040Phase 2
• Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)CompletedNCT03639623Phase 2

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic SteatohepatitisCompletedNCT03061721Phase 2

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Saroglitazar Magnesium in the Treatment of Non-Alcoholic SteatohepatitisCompletedNCT03863574Phase 2

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic FunctionCompletedNCT04469920Phase 1

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal FunctionCompletedNCT04446507Phase 1

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-CancerCompletedNCT04187898Phase 1

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary CholangitisCompletedNCT03112681Phase 2

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)CompletedNCT05283837Phase 3
• Study of Poziotinib in Japanese Patients With NSCLCTerminatedNCT04402008Phase 1/2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced MalignanciesTerminatedNCT04172597Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dLSuspendedNCT03097107Phase 2

  Sponsor listed in the registry: Zydus Therapeutics Inc.

• Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)TerminatedNCT04480138Phase 2
• A Study Of Zy-19489 Administered Via Oral Route To Investigate The Safety, Tolerability And Pharmacokinetics In Healthy Adult Human SubjectsCompletedNCT05206201Phase 1
• A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)CompletedNCT05186051Phase 2
• Desidustat in the Treatment of Chemotherapy Induced AnemiaCompletedNCT04667533Phase 1
• Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast CancerCompletedNCT01724866Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• A Study of IGN002 for Refractory NHLWithdrawnNCT02847949Phase 1

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Study of Poziotinib in Participants With HER2-Positive Metastatic Breast CancerCompletedNCT02659514Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Phase 1, Dose-Escalation Study of IGN002 in NHL SubjectsTerminatedNCT02519270Phase 1

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and CyclophosphamideCompletedNCT02953340Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)CompletedNCT02643420Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.TerminatedNCT00322218Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)TerminatedNCT00384111Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like TherapyTerminatedNCT01510184Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Desidustat in the Treatment of Anemia in CKD on Dialysis PatientsCompletedNCT04215120Phase 3
• Desidustat in the Treatment of Anemia in CKDCompletedNCT04012957Phase 3
• Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)TerminatedNCT00743184Phase 2

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma PatientsTerminatedNCT01420679Phase 3

  Sponsor listed in the registry: Spectrum Pharmaceuticals, Inc · First submitted before Spectrum Pharmaceuticals, Inc became part of Zydus Lifesciences Limited

• A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy VolunteersCompletedNCT04972188Phase 1